Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | BMS-986460 |
Synonyms | |
Therapy Description |
BMS-986460 is a ligand-directed degrader comprising a E3 ubiquitin ligase-binding moiety linked to a moiety targeting a prostate-specific tumor-associated antigen (TAA), which potentially inhibits growth of TAA-expressing tumor cells (NCI Drug Dictionary). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
BMS-986460 | BMS986460|BMS 986460 | BMS-986460 is a ligand-directed degrader comprising a E3 ubiquitin ligase-binding moiety linked to a moiety targeting a prostate-specific tumor-associated antigen (TAA), which potentially inhibits growth of TAA-expressing tumor cells (NCI Drug Dictionary). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT06067841 | Phase I | BMS-986460 | A Study to Assess BMS-986460 in Participants With Metastatic Castration-resistant Prostate Cancer | Recruiting | USA | 0 |